Core Viewpoint - Xuan Zhu Bio-B (02575) has seen a significant stock price increase, rising over 7% and currently trading at 58.45 HKD, with a transaction volume of 10.77 million HKD, following the inclusion of its innovative drug, Palbociclib, in the national medical insurance drug list [1] Group 1 - The National Healthcare Security Administration announced the adjustment results of the national medical insurance drug list on December 7, 2025, which includes Xuan Zhu Bio's CDK4/6 inhibitor, Palbociclib, providing new insurance reimbursement benefits for patients with advanced breast cancer [1] - The national medical insurance for Palbociclib will officially take effect on January 1, 2026, which is expected to significantly enhance the accessibility of the drug and reduce the financial burden on patients [1]
港股异动 | 轩竹生物-B(02575)再涨超7% 吡洛西利片医保落地 有望显著提升吡洛西利可及性